Zurück geht es hier Grüezi! Sie wurden auf finanzen.ch, unser Portal für Schweizer Anleger, weitergeleitet.  Zurück geht es hier.

Rare Holdings Aktie 2945123 / ZAE000092714

30.10.2025 14:09:31

Rare earths to be in deficit for 15 years, says Rainbow CEO

A SUPPLY deficit in rare earths was likely to exist for at least a decade even as the US rushes to secure deals for the minerals.“I believe that there’s not going to be enough supply coming into the market in the next 15 years,” said George Bennett, CEO of Rainbow Rare Earths. “Even if new rare earth sources are found in Greenland or in Ukraine, these projects are 20 years away from production.”Rainbow Rare Earths, a UK-listed firm, intends to produce rare earths neodynium and praseodymium from its proposed $326m Phalaborwa project in South Africa’s Northern Cape province. It is developing state-of-the-art processing technology in order to access tailings of phosphogypsum, stockpiled from previous phosphate mining.First production was still on track for 2028 despite delays in the completion of a definitive feasibility study. Commenting in a presentation on Wednesday, Bennett said the DFS would result in capital and operating savings.“I’m not going to make excuses for the delay. I believe we will deliver for our shareholders a de-risked project as well as a far better project in terms of project economics, NPV, capex, and so forth. So yes, we do have a delay, but in the overall scheme of things, this is a very fast-tracked project that’s coming to the market in terms of production.”“We are basically like a Ferrari on a racetrack in terms of from cradle to grave of the Rainbow project at Phalaborwa.”US president Donald Trump this week signed a series of deals on his visit to Asia to secure rare earths which have broad uses in the electric mobility, robotics, and defence industries. The deals were with Japan, Malaysia, Thailand, Vietnam and Cambodia in an effort to grab some market share from China, which dominates downstream supply of the minerals.The US government’s International Development Finance has pledged $50m in equity for the Phalaborwa project for a stake in TechMet, an 11.7% shareholder in Rainbow. TechMet is run by Brian Menell whose family helped build the Anglovaal group.“The percentage of equity they get will be based on forward forecast rare earth pricing, which is very positive, as we all know, and it will be based on the final NPV value of the project,” said Bennett.Speaking during Australian Prime Minister Anthony Albanese’s visit to the White House, Trump said that “in about a year from now we’ll have so much critical minerals and rare earths that you won’t know what to do with them”, according to a report by the BBC.Trump added that “they’ll be worth $2”, suggesting prices for rare earths would plummet as supply soared. At the moment, however, prices have increased to about $80/kg, a one third lift which was the result of a supply deal between NP Materials and the US which has undertaken to buy the minerals at a floor price of $110/kg.The post Rare earths to be in deficit for 15 years, says Rainbow CEO appeared first on Miningmx.Weiter zum vollständigen Artikel bei Mining.com

Analysen zu Rare Holdings Ltd.

  • Alle
  • Kaufen
  • Hold
  • Verkaufen
  • ?
Zu diesem Datensatz liegen uns leider keine Daten vor.
Eintrag hinzufügen

Erfolgreich hinzugefügt!. Zu Portfolio/Watchlist wechseln.

Es ist ein Fehler aufgetreten!

Kein Portfolio vorhanden. Bitte zusätzlich den Namen des neuen Portfolios angeben. Keine Watchlisten vorhanden. Bitte zusätzlich den Namen der neuen Watchlist angeben.

CHF
Hinzufügen

Etienne Jornod (OM Pharma): Führung, Erfolg & Pharma-Strategie- zu Gast im BX Morningcall

Im BX Morning Call spricht die Schweizer Unternehmer-Ikone Etienne Jornod (OM Pharma) mit François Bloch und Olivia Hähnel (BX Swiss) über Führung, Wachstum, Kooperationen, seine Zeit bei der NZZ und darüber, warum Zuhören der wichtigste Leadership-Skill ist.

Die perfekte Folge für alle, die sich für Pharmastrategien, Galenica/Vifor und Unternehmertum interessieren.

🎯 Themen im Interview mit Etienne Jornod (OM Pharma)

– Antrieb und Führungsphilosophie eines Unternehmers
– Erfolgsweg von Galenica – Lehren aus Jahrzehnten Führung
– Frauenquote, Teamkultur und Leadership bei OM Pharma
– Internationale Expansion: China, USA und neue Märkte
– Forschung, Druck und Verantwortung in der Pharmaindustrie
– Inspiration, Balance und persönliche Haltung zum Erfolg
– Zukunftsvisionen: Schweiz, Unternehmertum und Investments

👉🏽 https://bxplus.ch/bx-musterportfolio/

Etienne Jornod (OM Pharma): Führung, Erfolg & Pharma-Strategie- zu Gast im BX Morningcall

Mini-Futures auf SMI

Typ Stop-Loss Hebel Symbol
Short 12’787.24 19.72 BWDSCU
Short 13’059.96 13.87 B7ZS2U
Short 13’578.71 8.76 UJOBSU
SMI-Kurs: 12’301.21 30.10.2025 17:24:27
Long 11’737.17 19.41 SHFB5U
Long 11’450.10 13.42 BK5S8U
Long 10’950.93 8.79 BPOSGU
Die Produktdokumentation, d.h. der Prospekt und das Basisinformationsblatt (BIB), sowie Informationen zu Chancen und Risiken, finden Sie unter: https://keyinvest-ch.ubs.com